March 19, 2026
Memorial Sloan Kettering doesn't do HIPEC. Not for colorectal peritoneal metastases. After PRODIGE 7 was published in 2021, the surgical oncology world had to reckon with an uncomfortable finding: adding oxaliplatin-based HIPEC to CRS showed no survival benefit over CRS alone and was associated with more complications. Many centers continued to offer HIPEC anyway, citing different drug protocols or patient selection criteria. MSK moved toward Cytoreductive Surgery (CRS) combined with EPIC —…
More
raig daniels